Sutro Biopharma (STRO) Research & Development (2017 - 2025)
Sutro Biopharma recorded quarterly Research & Development of $36.6 million in Q4 2025, down 8.06% quarter-over-quarter from $39.9 million in Q3 2025, and down 48.42% year-over-year from $71.0 million in Q4 2024.
Sutro Biopharma's Research & Development history runs 9 years deep, the most recent figure standing at $36.6 million for Q4 2025.
- In Q4 2025, Research & Development fell 48.42% year-over-year to $36.6 million; the TTM figure through Dec 2025 stood at $166.4 million (down 33.97% YoY), while the FY2025 annual figure was $166.4 million, down 33.97% from the prior year.
- Research & Development came in at $36.6 million for Q4 2025 at Sutro Biopharma, down from $39.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $71.0 million in Q4 2024 to a low of $22.6 million in Q1 2021.
- A 5-year average of $42.0 million and a median of $39.6 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 49.12% in 2024 and slumped 48.42% in 2025, its largest moves.
- Sutro Biopharma's Research & Development stood at $29.9 million in 2021, then jumped by 44.13% to $43.1 million in 2022, then increased by 24.64% to $53.8 million in 2023, then surged by 32.12% to $71.0 million in 2024, then plunged by 48.42% to $36.6 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $36.6 million, $39.9 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | 36.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.64 Mn |
| Sep 30, 2025 | 39.85 Mn |
| Jun 30, 2025 | 38.33 Mn |
| Mar 31, 2025 | 51.60 Mn |
| Dec 31, 2024 | 71.04 Mn |
| Sep 30, 2024 | 62.11 Mn |
| Jun 30, 2024 | 62.02 Mn |
| Mar 31, 2024 | 56.88 Mn |
| Dec 31, 2023 | 53.77 Mn |
| Sep 30, 2023 | 45.67 Mn |
| Jun 30, 2023 | 41.59 Mn |
| Mar 31, 2023 | 39.40 Mn |
| Dec 31, 2022 | 43.14 Mn |
| Sep 30, 2022 | 31.71 Mn |
| Jun 30, 2022 | 32.33 Mn |
| Mar 31, 2022 | 29.99 Mn |
| Dec 31, 2021 | 29.93 Mn |
| Sep 30, 2021 | 26.60 Mn |
| Jun 30, 2021 | 25.31 Mn |
| Mar 31, 2021 | 22.56 Mn |
| Dec 31, 2020 | 22.74 Mn |
| Sep 30, 2020 | 19.36 Mn |
| Jun 30, 2020 | 17.24 Mn |
| Mar 31, 2020 | 17.62 Mn |
| Dec 31, 2019 | 17.39 Mn |
| Sep 30, 2019 | 16.90 Mn |
| Jun 30, 2019 | 16.14 Mn |
| Mar 31, 2019 | 15.18 Mn |
| Dec 31, 2018 | 14.79 Mn |
| Sep 30, 2018 | 12.64 Mn |
| Jun 30, 2018 | 13.75 Mn |
| Mar 31, 2018 | 13.08 Mn |
| Dec 31, 2017 | 15.14 Mn |
| Sep 30, 2017 | 13.67 Mn |